Cutaneous Leishmaniasis Completed Phase 1 Trials for Aluminum hydroxide (DB06723)

Also known as: Leishmaniasis, Cutaneous / Cutaneous leishmaniasis (disorder)

IndicationStatusPhase
DBCOND0028439 (Cutaneous Leishmaniasis)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00001906Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as AdjuvantsTreatment